Previous Article | Next Article 
Infection and Immunity, April 2001, p. 2732-2735, Vol. 69, No. 4
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.2732-2735.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Generation and Characterization of a Defined Mutant
of Streptococcus suis Lacking Suilysin
Andrew G.
Allen,1,
Steven
Bolitho,1
Heather
Lindsay,1
Shahid
Khan,1
Clare
Bryant,1
Pam
Norton,2
Philip
Ward,2
James
Leigh,2
Jeremy
Morgan,2
Helen
Riches,2
Sarah
Eastty,2 and
Duncan
Maskell1,*
Centre for Veterinary Science, Department of
Clinical Veterinary Medicine, University of Cambridge, Cambridge
CB3 0ES,1 and Institute for Animal
Health, Compton, Newbury, Berkshire RG20 7NN,2
United Kingdom
Received 24 July 2000/Returned for modification 29 August
2000/Accepted 2 January 2001
 |
ABSTRACT |
A defined allelic-replacement mutant of the sly gene,
encoding a thiol-activated cytolysin, from a European isolate of
Streptococcus suis serotype 2 was generated and
characterized. Unlike the parental strain, it is nonhemolytic,
noncytotoxic for cultured macrophage-like cells, avirulent in a mouse
infection model, yet only slightly attenuated in a porcine model of
systemic infection.
 |
TEXT |
Streptococcus suis has
been described as the etiological agent for a number of infectious
disease syndromes in pigs, including arthritis, septicemia, meningitis,
and pneumonia. S. suis produces a secreted hemolysin
(suilysin) which has been suggested as playing a role in virulence
(2, 4-7, 10). In order to investigate the role played by
suilysin in the pathogenesis of a European serotype 2 isolate of
S. suis, we generated a defined allelic-replacement mutant
of the sly gene and compared the wild-type organism with the
sly mutant in a number of assays.
Bacterial strains and media.
S. suis type 2 strain
P1/7 was grown on Columbia agar (Oxoid) containing 10% defibrinated
horse blood or in liquid cultures of Todd-Hewitt broth (Oxoid)
supplemented with 7% fetal calf serum (FCS) (Gibco).
Allelic-replacement mutants of S. suis were maintained on 1 µg of erythromycin (Sigma) per ml.
Mutagenesis of the suilysin gene from S. suis type
2.
An erythromycin resistance gene cassette was introduced into an
EcoRV site within a 1,278-bp fragment of the sly
gene, contained in the vector pT7-Blue (Stratagene), amplified by PCR
using primers suis1 (5'-AGCTTGACTTACGAGCCACAAGAG-3') and
suis2 (5'-CCACCATTCCCAAGCTAATCCTGT-3') with chromosomal DNA
from P1/7 as a template. The resulting plasmid, pSUI-erm, contains the
erm gene in the same orientation as the sly gene.
Plasmid pSUI-erm was introduced into P1/7 by electroporation (22.5 V/cm, 25 µF, and 1,000
). A transformant which had undergone a
double-crossover event, confirmed by Southern hybridization and PCR,
with concomitant insertion mutation of the sly gene, was
isolated and named S7c.
Phenotypic analysis of S7c.
Overnight growth of suilysin
mutant S7c on Columbia blood agar plates revealed no
-hemolysis.
Secreted proteins from anaerobically grown overnight cultures of P1/7
and S7c were concentrated 100-fold by ammonium sulfate (50%, wt/vol)
precipitation; then 10 µl each of these preparations was spotted onto
a Columbia horse blood agar plate and incubated at 37°C for 30 min.
The proteins from P1/7 show clear zones of hemolysis, whereas there is
a complete absence of hemolytic activity in the proteins obtained from
S7c (Fig. 1a). The hemolytic activity
from the wild-type parental bacteria was enhanced by the addition of
-mercaptoethanol, as previously reported (7) (Fig. 1a).

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 1.
Characterization of P1/7 and S7c culture supernatants.
(a) Overnight culture supernatants from wild type P1/7 (wt) and S7c
(S7c) were concentrated 100-fold by ammonium sulfate precipitation, and
10-µl samples, indicated by circles, were overlaid onto a 7%
(vol/vol) horse blood agar plate, followed by incubation at 37°C for
60 min. Samples in track B were treated with -mercaptoethanol to a
final concentration of 1 mM. PBS, phosphate-buffered saline. (b)
Western blot of culture supernatants from P1/7 and S7c using
antisuilysin monoclonal antibody. Proteins secreted from overnight
culture supernatants from P1/7 (track A) and S7c (track B) were
concentrated 25 times, separated on a polyacrylamide gel, and Western
blotted onto nitrocellulose, followed by development with a monoclonal
antibody specific for suilysin. The band corresponding to suilysin in
track A is completely absent from track B. Molecular weights are in
thousands.
|
|
The lack of expression of suilysin was confirmed by Western blotting.
Supernatants from aerobically grown cultures of both P1/7 and S7C
(sterilized using a 0.22-µm-pore-size filter and concentrated 25-fold
using Amicon filters) were probed with a monoclonal antibody
(INT-STS-28-02; A. C. Jacobs, Intervet) raised against purified
suilysin. An immunoreactive protein with the expected molecular weight
(54,000) was clearly present in the supernatant from P1/7 (Fig. 1b,
track A), whereas there was no immunoreactive material present in that
from S7c (Fig. 1b, track B). These results show that an
allelic-replacement insertion mutant lacking functional sly
was generated in S. suis and that this mutant was not hemolytic.
Cell culture and cytotoxicity assay.
Murine macrophage-like
J774.2 cells were split into 96-well plates (approximately 1.5 × 105 cells/well) and maintained in Dulbecco modified Eagle
medium supplemented with 3% FCS and 2 mM glutamine (assay buffer).
Bacterial inocula (5 × 107 CFU per 100 µl, in assay
buffer), generated from overnight cultures of P1/7 and S7c, were added
to three experimental wells and incubated at 37°C with 5% carbon
dioxide for 3 and 5 h. Relative cytotoxicity was assayed as
lactate dehydrogenase (LDH) release as determined by the CytoTox96 kit
(Promega). The experiment was repeated on three separate occasions
(Fig. 2). The parental strain, P1/7, caused extensive damage to cell monolayers in a time-dependent manner.
In comparison, S7c elicited only approximately 4% of maximal LDH
release after 5 h of incubation. Bacterial viable counts during the experiment revealed identical numbers of CFU for P1/7 and S7c.
These experiments show that S. suis efficiently kills J774.2 cells and that this effect is dependent on the presence of suilysin, which is thus probably the only cytolysin produced by S. suis.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of cytotoxicities of P1/7 and S7c for J774.2
cells. Monolayers of J774. 2 cells (2 × 105 cells)
were infected with P1/7 (P) or S7c (S). Relative levels of LDH released
at 3 and 5 h were measured and plotted as percentages of the maximum
lysis achieved by chemical treatment. Experiments were performed in
triplicate for each datum point. Where no bars are present, the lysis
was effectively zero. Spontaneous lysis (C) occurred without the
addition of bacteria. It is clear that wild-type bacteria cause
substantial lysis of the cell monolayer, whereas the mutant lacking
suilysin is unable to lyse the cells.
|
|
Mouse infection experiments.
Overnight cultures of P1/7 and
S7c, grown in Todd-Hewitt broth containing 10% FCS, were diluted in
the same medium to achieve 108, 107,
106, and 105 CFU/0.5-ml dose. These 0.5-ml
inocula were introduced intraperitoneally into 5-week-old female BALB/c
mice, in groups of five mice per inoculum. Mice were monitored over a
period of 1 week, during which deaths were recorded and moribund
animals were humanely killed. Inoculation of 108 and
107 wild-type bacteria killed 9 of 10 mice and 8 of 10 mice, respectively, over the two experiments, within 48 h,
providing 50% lethal doses (9) of log 6.45 and log 6.73, respectively, whereas all mice infected with S7c survived. These data
show unequivocally that mutation of suilysin prevents S. suis from killing mice via the intraperitoneal route of infection.
Pig infection experiment.
Pigs, aged between 35 and 40 days,
were obtained from Cotswold Pigs Ltd. (Colsterworth Farm, United
Kingdom). Fourteen days prior to challenge, animals were screened for
the presence of major pathogens and injected with ceftiofur (Excenel;
Pharmacia & Upjohn Ltd.) for three consecutive days. Bacteria for
challenge were grown overnight in brain heart infusion broth at 37°C
and were subcultured in the same medium for 6 h at 37°C.
Cultures were diluted in phosphate-buffered saline (pH 7.2), and each
animal was challenged by intravenous injection of 1 ml of
phosphate-buffered saline containing between 1 × 106
and 5 × 106 CFU of either strain S7c (group 1) or
P1/7 (group 2). Animals were monitored for clinical signs of disease
every 3 h; piglets showing marked signs of illness were killed for
postmortem examination. Surviving animals were killed for postmortem
examination 44 h postinfection. At postmortem, a visual inspection
was made in order to detect pathological lesions and swabs were taken
from heart blood, the lateral ventricle of the brain, the lungs, the serous cavity, and two limbs for bacterial examination. Results (lesion
scores, bacteriology, survival times) between groups were analyzed
statistically using Student's t test via MINITAB release 12.1 for Windows. Tests were performed assuming equal variance and were
repeated assuming unequal variance where necessary.
The results of the challenge experiment are summarized in Table
1. Two pigs infected with S7c and one
infected with P1/7 showed signs of clinical disease by 12 h
postinfection, with marked lameness, shivering, and vomiting. By
15 h postinfection, three pigs challenged with S7c and all five
infected with P1/7 were affected, typical signs being dullness, swollen
joints, and dyspnea. Three pigs infected with P1/7 and three infected
with S7c required euthanasia commencing 21 h postinfection, due to
severe lameness. A fourth pig infected with P1/7 showed signs of
meningitis (wide-based stance, rigid posture, ataxia, and muscle
tremors). At 44 h postinfection the experiment was terminated, by
which time only one pig infected with P1/7 and two pigs infected with
S7c were left alive. Mean survival times were not significantly
different between groups.
S. suis was isolated from all pigs following challenge.
Thirty colonies from the five pigs challenged with S7c were tested by
PCR for the suilysin gene. In all these colonies only the mutant allele
was detected, whereas all colonies isolated from P1/7-infected animals
had intact suilysin genes (8). Bacterial numbers were assessed semiquantitatively (from a value of 0 for no growth to a value
of 4 for heavy growth). Bacterial growth in vivo was more profuse in
tissues from organs of pigs challenged with P1/7 than in those from
pigs challenged with S7c, but the differences were not significantly
different statistically (Table 1). Bacteriology scores of 3 or 4 from
heart blood, serous exudates, lungs, and joints were common in pigs
challenged with P1/7, whereas only 3 of 30 sites in pigs challenged
with S7c had scores of 3 and no sites had scores of 4. The only animal
with marked levels of S. suis in the brain was also the only
animal (infected with P1/7) that showed signs of meningitis. S. suis was also isolated from the brains of two animals euthanatized
for lameness (one infected with P1/7 and one with S7c), but in each
case growth was scant (scored as 1).
The main lesions observed at postmortem examination were serous or
purulent arthritis and periarticulitis of main limb joints with
pericarditis and pleurisy. Joint lesions were observed in pigs in both
groups. Lesions of pericarditis were mainly restricted to pigs
challenged with P1/7, with extensive gelatinous pericarditis, restricted pleurisy, and scant accumulations of pus along the margins
of the lung lobes being present in the majority of pigs in this group.
Mild peritonitis was observed in five pigs, some from each group. The
total lesion scores were calculated and were significantly higher in
pigs challenged with P1/7 (Table 1). The one pig (infected with P1/7)
that showed signs of meningitis also revealed positive histological
signs of meningitis. Bacteria were recovered from the brain of a pig
infected with S7c, but no histological confirmation of meningitis was apparent.
These experiments strongly indicate that suilysin is not required for
infection with S. suis to progress to clinically apparent disease once the bacteria have reached the circulatory system. Some
evidence in these limited experiments supports a role for suilysin in
increasing the severity of clinical signs and indicates that it may be
involved in allowing S. suis colonization of the organs to
reach higher levels. These data also indicate that suilysin is not
required for infection of the meninges.
It has been suggested that suilysin is required for colonization and
for the establishment of the initial stages of infection in pigs
(8). S. suis can invade and lyse a monolayer of
human laryngeal epithelial cells (HEp-2), with more virulent strains able to adhere to and invade the cells significantly more efficiently than less virulent or avirulent strains. With all strains tested, cytotoxicity was abrogated by the addition of a neutralizing
antisuilysin monoclonal antibody, suggesting that suilysin is the only
cytotoxin secreted by S. suis. These data correlate well
with our observation that S7c is noncytotoxic for J774.2 cells.
S. suis also adheres to human brain microvascular
endothelial cells (BMEC), a constituent of the blood-brain barrier
(BBB) (1). In these experiments only some strains were
cytotoxic for these cells, and this was related to the presence of
suilysin, with cytotoxicity inhibited by cholesterol and antisuilysin
antibodies. Invasion of the BMEC was not observed under any conditions,
unlike with other meningitis-causing bacteria, such as group B
streptococci, Streptococcus pneumoniae, and
Escherichia coli K1. It was proposed that S. suis
may pass through the BBB by invading the intracellular junctions of
BMEC monolayers and that suilysin may play a role in this
(1). In the experiments reported here, the recovery of
bacteria from the brain of a pig infected with S7c indicates that
S. suis not producing suilysin can still cross the BBB in
this species. Thus, suilysin may aid penetration of the BBB, but it is
not essential for this process. Additionally, suilysin has been shown
not to induce the release of inflammatory mediators from in
vitro-cultured macrophages and so is probably not important in the
development of clinical signs of meningitis (11).
Similarly, pneumolysin does not appear to have a role in the
inflammatory response in the cerebrospinal fluid in a rabbit meningitis
model which leads to the development of disease attributed to cell wall
components (3, 12, 13).
The data in this study do not rule out roles for suilysin at a number
of stages in the development of disease. Following colonization of the
upper respiratory tract, suilysin may aid entry of S. suis through the epithelium. In these initial studies, we have used the
intravenous route of infection in pigs in order to look for major
differences in pathogenicity in systemic stages of the disease, but
this does not allow investigation of any role for suilysin during
colonization and infection from the tonsils, and this may be a location
where suilysin contributes to pathogenesis. To investigate this will
require an intranasal model of infection, which can be highly variable
and thus needs large numbers of animals; this was beyond the scope of
the present study.
The comparison between pig and mouse models of infection provides
insight into the relevance of using animal models in drawing conclusions regarding pathogenicity. However, it must be stated that
direct comparison of the models is difficult to make, since the modes
of infection and the infectious doses were different between the
models. In addition, lethality assays for sly+
and sly mutant strains of S. suis in the pig
model could not be performed for ethical reasons. In summary, these
animal infection data leave the precise role of suilysin in the
pathogenesis of disease caused by S. suis unclear, with
further investigation by extensive experimentation in different pig
models required. Future studies will be aimed at identifying whether
suilysin is involved in the early events required for colonization and
invasion in the initiation of disease.
 |
ACKNOWLEDGMENTS |
The Wellcome Trust RCDF (051033) awarded to A. G. Allen
supported the work performed at the University of Cambridge, and the Institute for Animal Health, Compton, is supported by the BBSRC.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Centre for
Veterinary Science, Department of Clinical Veterinary Medicine,
University of Cambridge, Madingley Rd., Cambridge, CB3 0ES, United
Kingdom. Phone: 44 1223 339868. Fax: 44 1223 337610. E-mail:
djm47{at}cam.ac.uk.
Present address: Arrow Therapeutics Ltd., Carshalton, Surrey,
SM5 4DS, United Kingdom.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Charland, N.,
V. Nizet,
C. E. Rubens,
K. S. Kim,
S. Lacouture, and M. Gottschalk.
2000.
Streptococcus suis serotype 2 interactions with human brain microvascular endothelial cells.
Infect. Immun.
68:637-643[Abstract/Free Full Text].
|
| 2.
|
Feder, I.,
M. M. Chengappa,
B. Fenwick,
M. Rider, and J. Staats.
1994.
Partial characterization of Streptococcus suis type 2 hemolysin.
J. Clin. Microbiol.
32:1256-1260[Abstract/Free Full Text].
|
| 3.
|
Friedland, I. R.,
M. M. Paris,
S. Hickey,
S. Shelton,
K. Olsen,
J. C. Paton, and G. H. McCracken.
1995.
The limited role of pneumolysin in the pathogenesis of pneumococcal meningitis.
J. Infect. Dis.
172:805-809[Medline].
|
| 4.
|
Gottschalk, M. G.,
S. Lacouture, and J. D. Dubreuil.
1995.
Characterization of Streptococcus suis capsular type 2 haemolysin.
Microbiology
141:189-195[Abstract].
|
| 5.
|
Jacobs, A. A.,
A. J. van den Berg,
J. C. Baars,
B. Nielsen, and L. W. Johannsen.
1995.
Production of suilysin, the thiol-activated haemolysin of Streptococcus suis, by field isolates from diseased pigs.
Vet. Rec.
137:295-296[Medline].
|
| 6.
|
Jacobs, A. A.,
A. J. van den Berg, and P. L. Loeffen.
1996.
Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis.
Vet. Rec.
139:225-228[Abstract/Free Full Text].
|
| 7.
|
Jacobs, A. A. C.,
P. L. W. Loeffen,
A. J. G. van den Berg, and P. K. Storm.
1994.
Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis.
Infect. Immun.
62:1742-1748[Abstract/Free Full Text].
|
| 8.
|
Norton, P. M.,
C. Rolph,
P. N. Ward,
R. W. Bentley, and J. A. Leigh.
1999.
Epithelial invasion and cell lysis by virulent strains of Streptococcus suis is enhanced by the presence of suilysin.
FEMS Immunol. Med. Microbiol.
26:25-35[CrossRef][Medline].
|
| 9.
|
Reed, L. J., and H. Muench.
1938.
A simple method of estimating fifty percent endpoints.
Am. J. Hyg.
27:493-497.
|
| 10.
|
Segers, R. P.,
T. Kenter,
L. A. de Haan, and A. A. Jacobs.
1998.
Characterisation of the gene encoding suilysin from Streptococcus suis and expression in field strains.
FEMS Microbiol. Lett.
167:255-261[CrossRef][Medline].
|
| 11.
|
Segura, M.,
J. Stankova, and M. Gottschalk.
1999.
Heat-killed Streptococcus suis capsular type 2 strains stimulate tumor necrosis factor alpha and interleukin-6 production by murine macrophages.
Infect. Immun.
67:4646-4654[Abstract/Free Full Text].
|
| 12.
|
Tomasz, A., and K. Saukkonen.
1989.
The nature of cell wall-derived inflammatory components of pneumococci.
Pediatr. Infect. Dis. J.
8:902-903[Medline].
|
| 13.
|
Tuomanen, E.,
A. Tomasz,
B. Hengstler, and O. Zak.
1985.
The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis.
J. Infect. Dis.
151:535-540[Medline].
|
Infection and Immunity, April 2001, p. 2732-2735, Vol. 69, No. 4
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.2732-2735.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Baums, C. G., Kaim, U., Fulde, M., Ramachandran, G., Goethe, R., Valentin-Weigand, P.
(2006). Identification of a Novel Virulence Determinant with Serum Opacification Activity in Streptococcus suis.. Infect. Immun.
74: 6154-6162
[Abstract]
[Full Text]
-
Fontaine, M. C., Perez-Casal, J., Willson, P. J.
(2004). Investigation of a Novel DNase of Streptococcus suis Serotype 2. Infect. Immun.
72: 774-781
[Abstract]
[Full Text]
-
Harel, J., Martinez, G., Nassar, A., Dezfulian, H., Labrie, S. J., Brousseau, R., Moineau, S., Gottschalk, M.
(2003). Identification of an Inducible Bacteriophage in a Virulent Strain of Streptococcus suis Serotype 2. Infect. Immun.
71: 6104-6108
[Abstract]
[Full Text]
-
Segura, M., Gottschalk, M.
(2002). Streptococcus suis Interactions with the Murine Macrophage Cell Line J774: Adhesion and Cytotoxicity. Infect. Immun.
70: 4312-4322
[Abstract]
[Full Text]
-
de Greeff, A., Buys, H., Verhaar, R., Dijkstra, J., van Alphen, L., Smith, H. E.
(2002). Contribution of Fibronectin-Binding Protein to Pathogenesis of Streptococcus suis Serotype 2. Infect. Immun.
70: 1319-1325
[Abstract]
[Full Text]
-
King, S. J., Heath, P. J., Luque, I., Tarradas, C., Dowson, C. G., Whatmore, A. M.
(2001). Distribution and Genetic Diversity of Suilysin in Streptococcus suis Isolated from Different Diseases of Pigs and Characterization of the Genetic Basis of Suilysin Absence. Infect. Immun.
69: 7572-7582
[Abstract]
[Full Text]